Drug Trial Radar · NCT00577018
Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic Constipation
Last checked: Nov 20, 2026Latest source record: May 29, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
755
Actual
Start
Aug 1998
Primary completion
Sep 1999
Study completion Sep 1999
Sponsor
- Lead sponsor
- MovetisIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety profile of 4 mg prucalopride in the treatment of chronic constipation.
Conditions
- Constipation
Interventions
PrucaloprideDrug
4 mg o.d.
PrucaloprideDrug
1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
PlaceboOther
o.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with an average of ≥3 SCBM/weekTime frame: 4 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.